The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 02, 2021

Filed:

Nov. 28, 2017
Applicant:

University of Florida Research Foundation, Incorporated, Gainesville, FL (US);

Inventors:

Arun Srivastava, Gainesville, FL (US);

Li Zhong, Gainesville, FL (US);

Sergei Zolotukhin, Gainesville, FL (US);

George Vladimirovich Aslanidi, Astin, MN (US);

Mavis Agbandje-McKenna, Gainesville, FL (US);

Kim M. Van Vliet, Gainesville, FL (US);

Chen Ling, Gainesville, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/76 (2015.01); C07K 14/005 (2006.01); A61K 48/00 (2006.01); A61K 39/00 (2006.01); C12N 15/86 (2006.01); C12N 15/864 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 35/76 (2013.01); A61K 39/0011 (2013.01); A61K 48/005 (2013.01); A61K 48/0008 (2013.01); A61K 48/0091 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12N 15/8645 (2013.01); A61K 2039/5158 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14132 (2013.01); C12N 2750/14142 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01); C12N 2750/14171 (2013.01); C12N 2810/6027 (2013.01);
Abstract

Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.


Find Patent Forward Citations

Loading…